BioCentury
ARTICLE | Company News

Vertex, J&J, Merck deal

May 7, 2007 7:00 AM UTC

VRTX received a $15 million milestone payment from JNJ's Janssen Pharmaceutica K.K. subsidiary under a deal that gave JNJ an exclusive license to develop and commercialize VX-950 to treat HCV in Europe, South America, the Middle East, Africa and Australia (see BioCentury, July 3, 2006). The payment was triggered by the start of the Phase IIb PROVE 3 trial (see BioCentury, Feb. 12). To date, VRTX has received $30 million in milestones from JNJ under the deal, in addition to $165 million up front and undisclosed R&D reimbursement. ...